Additive Therapie der Pseudomonas-Sepsis mit Pseudomonas-Immunglobulin

[1]  K. Jakobs,et al.  Pseudomonas exotoxin A prevents beta-adrenoceptor-induced upregulation of Gi protein alpha-subunits and adenylyl cyclase desensitization in rat heart muscle cells. , 1990, Molecular pharmacology.

[2]  J. Larrick,et al.  Isolation and characterization of a human monoclonal antibody that recognizes epitopes shared by Pseudomonas aeruginosa immunotype 1, 3, 4, and 6 lipopolysaccharides , 1989, Infection and immunity.

[3]  J. Pennington,et al.  Treatment of experimental Pseudomonas aeruginosa pneumonia with a human IgM monoclonal antibody. , 1989, The Journal of infectious diseases.

[4]  R. Schorer,et al.  Adjuvante Therapie mit Pseudomonas-Immunglobulin , 1989 .

[5]  I. Class,et al.  [Adjuvant therapy with pseudomonas immunoglobulin in artificially ventilated patients at a surgical intensive care unit]. , 1989, Anasthesie, Intensivtherapie, Notfallmedizin.

[6]  K. Werdan,et al.  Homologous vs. heterologous desensitization of the adenylate cyclase system in heart cells. , 1988, European journal of pharmacology.

[7]  Y. Masuho,et al.  Immunoprotective human monoclonal antibodies against five major serotypes of Pseudomonas aeruginosa. , 1987, Journal of general microbiology.

[8]  J E Parrillo,et al.  Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. , 1987, Critical care medicine.

[9]  Y. Masuho,et al.  Characterization of a human monoclonal antibody to lipopolysaccharides of Pseudomonas aeruginosa serotype 5: a possible candidate as an immunotherapeutic agent for infections with P. aeruginosa. , 1985, The Journal of infectious diseases.

[10]  W. Knaus,et al.  APACHE II: a severity of disease classification system. , 1985 .

[11]  M. Collins,et al.  Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa. , 1984, The American journal of medicine.

[12]  M. Pollack,et al.  Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. , 1983, The Journal of infectious diseases.

[13]  E. Elebute,et al.  The grading of sepsis , 1983, The British journal of surgery.

[14]  L. S. Young,et al.  Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. , 1979, The Journal of clinical investigation.

[15]  D. Böhm.  Erfahrungen mit einem Pseudomonas-Immunglobulin bei beatmeten Patienten mit Pseudomonas-Pneumonie auf einer chirurgischen Intensivstation , 2005, Infection.

[16]  P. Boekstegers,et al.  Pseudomonas immunoglobulin therapy in patients with Pseudomonas sepsis and septic shock. , 1991, Antibiotics and Chemotherapy.

[17]  K. Werdan,et al.  A basic program for calculation of APACHE II and Elebute scores and sepsis evaluation in intensive care medicine. , 1991, Computers in biology and medicine.

[18]  B. Chernow.  Second Vienna Shock Forum , 1991 .

[19]  E. Erdmann,et al.  Preparation and culture of embryonic and neonatal heart muscle cells: modification of transport activity. , 1989, Methods in enzymology.

[20]  A. Fomsgaard,et al.  Preliminary study on treatment of septic shock patients with antilipopolysaccharide IgG from blood donors. , 1989, Scandinavian journal of infectious diseases.

[21]  K. Werdan,et al.  The use of scoring systems in patients with cardiogenic and septic shock. , 1989, Progress in clinical and biological research.

[22]  R. Grundmann,et al.  Der «Sepsisscore» von Elebute und Stoner zur Definition der postoperativen Sepsis auf der Intensivstation , 1988 .

[23]  T. Klöss,et al.  [Use of pseudomonas immunoglobulin in ventilated patients at an interdisciplinary surgical intensive care station]. , 1987, Infection.

[24]  D. Böhm.  [Experiences with a Pseudomonas immunoglobulin in ventilated patients with Pseudomonas pneumonia in a surgical intensive care station]. , 1987, Infection.